Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma

X
Trial Profile

Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabozantinib (Primary) ; Dacarbazine; Temozolomide
  • Indications Uveal melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Sep 2019 Primary endpoint (Proportion of Patients Without a Progression Free Survival Event at 4 Months (PFS4) has not been met published in the Clinical Cancer Research
    • 26 Sep 2019 Status changed from active, no longer recruiting to discontinued.
    • 26 Sep 2019 Interim results assessing the progression-free survival rate at 4 months of patients with uveal melanoma treated with cabozantinib or chemotherapy published in the Clinical Cancer Research
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top